ImmunoGen, Inc. Announces Webcast of Presentation and Q&A at the 34th Annual J. P. Morgan Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 34th Annual J. P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for 3:00 pm PT (6:00 pm ET) on January 12, 2016.

Following the presentation, Mr. Junius will be joined by other members of ImmunoGen’s management team for a question-and-answer session at 3:30pm PT (6:30 pm ET).

A webcast of the presentation and question-and-answer sessions will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancer and other solid tumors. A number of major healthcare companies have licensed limited rights to use ImmunoGen's ADC technology to develop anticancer therapies; it is used in Roche's marketed product, Kadcyla®. More information about the Company can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160104005110/en/

ImmunoGen, Inc.Carol Hausner, [e-mail]